| Reaction Details |
|---|
 | Report a problem with these data |
| Target | Adenosine receptor A2b |
|---|
| Ligand | BDBM50229886 |
|---|
| Substrate/Competitor | n/a |
|---|
| Meas. Tech. | ChEMBL_30307 (CHEMBL638561) |
|---|
| Ki | 38±n/a nM |
|---|
| Citation |  Baraldi, PG; Tabrizi, MA; Preti, D; Bovero, A; Romagnoli, R; Fruttarolo, F; Zaid, NA; Moorman, AR; Varani, K; Gessi, S; Merighi, S; Borea, PA Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists. J Med Chem47:1434-47 (2004) [PubMed] Article |
|---|
| More Info.: | Get all data from this article, Assay Method |
|---|
| |
| Adenosine receptor A2b |
|---|
| Name: | Adenosine receptor A2b |
|---|
| Synonyms: | AA2BR_HUMAN | ADENOSINE A2B | ADORA2B | Adenosine receptor A2B (A2B) | Adenosine receptors A2b | Adenosine receptors; A2a & A2b |
|---|
| Type: | G Protein-Coupled Receptor (GPCR) |
|---|
| Mol. Mass.: | 36341.22 |
|---|
| Organism: | Homo sapiens (Human) |
|---|
| Description: | n/a |
|---|
| Residue: | 332 |
|---|
| Sequence: | MLLETQDALYVALELVIAALSVAGNVLVCAAVGTANTLQTPTNYFLVSLAAADVAVGLFA
IPFAITISLGFCTDFYGCLFLACFVLVLTQSSIFSLLAVAVDRYLAICVPLRYKSLVTGT
RARGVIAVLWVLAFGIGLTPFLGWNSKDSATNNCTEPWDGTTNESCCLVKCLFENVVPMS
YMVYFNFFGCVLPPLLIMLVIYIKIFLVACRQLQRTELMDHSRTTLQREIHAAKSLAMIV
GIFALCWLPVHAVNCVTLFQPAQGKNKPKWAMNMAILLSHANSVVNPIVYAYRNRDFRYT
FHKIISRYLLCQADVKSGNGQAGVQPALGVGL
|
|
|
|---|
| BDBM50229886 |
|---|
| n/a |
|---|
| Name | BDBM50229886 |
|---|
| Synonyms: | 2-(3,4-Dimethoxy-phenyl)-N-[5-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-1-methyl-1H-pyrazol-3-yl]-acetamide | 2-(3,4-dimethoxyphenyl)-N-(5-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-1-methyl-1H-pyrazol-3-yl)acetamide | CHEMBL408186 |
|---|
| Type | Small organic molecule |
|---|
| Emp. Form. | C25H31N7O5 |
|---|
| Mol. Mass. | 509.5575 |
|---|
| SMILES | CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)-c1cc(NC(=O)Cc2ccc(OC)c(OC)c2)nn1C |
|---|
| Structure | 
|
|---|
Search and Browse
